Colivelin prolongs survival of an ALS model mouse

Tomohiro Chiba, Marina Yamada, Jumpei Sasabe, Kenzo Terashita, Sadakazu Aiso, Masaaki Matsuoka, Ikuo Nishimoto

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.

Original languageEnglish
Pages (from-to)793-798
Number of pages6
JournalBiochemical and Biophysical Research Communications
Issue number3
Publication statusPublished - 2006 May 12
Externally publishedYes


  • ADNF
  • ALS
  • Colivelin
  • Humanin
  • Neuroprotection
  • SOD1

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Colivelin prolongs survival of an ALS model mouse'. Together they form a unique fingerprint.

Cite this